This was confirmed by reduced tumour growth and increased immune activation in a mouse model of breast and colon cancer, in case LAIR-1, TGFβR2 and PD-1/PD-L1 inhibitors were administered simultaneously, as compared to separately [110]. The gene discussed is PDCD1; the disease is neoplasm.